Information Provided By:
Fly News Breaks for January 22, 2016
ALKS
Jan 22, 2016 | 05:54 EDT
UBS analyst Marc Goodman lowered his price target for Alkermes to $36 saying ALKS 5461 has a "very low probability" of getting approved following yesterday's trial failures, even if the third trial is successful. Goodman views the 44% decline in shares yesterday as appropriate and does not see a favorable risk/reward at these levels. The analyst expects Aristada's launch to disappoint and keeps a Neutral rating on Alkermes.
News For ALKS From the Last 2 Days
There are no results for your query ALKS